Lantheus Holdings, Inc. — News

Are DSGR, LNTH, ATKR Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Aug. 7, 2026

gurufocus.com - 2026-08-07 15:00:00

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws

prnewswire.com - 2026-08-07 14:16:00

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (“KSF”) are investigating the propos

gurufocus.com - 2026-08-07 12:00:00

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Lantheus Holdings, Inc. (NasdaqGM: LNTH) to Curium US Holdings LLC. Under the terms of the proposed transaction, shareholders of Lantheus will receive $102.50 per share in cash, plus non-transferable Contingent Value Rights providing for up to $12.00 per share in potential additional cash payments,.

businesswire.com - 2026-08-07 11:02:00

Worldwide revenue of $388.2 million in the second quarter of 2026 GAAP fully diluted earnings per share of $1.11, compared to $1.12 in the second quarter of 2025 Adjusted fully diluted earnings per share of $1.55, compared to $1.57 in the second quarter of 2025 Announced on August 3, 2026 that it has entered into a definitive agreement to merge with Curium under which Curium US Holdings LLC will acquire all outstanding shares in an all-cash transaction that represents a total transaction value of up to approximately $8.0 billion BEDFORD, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today reported financial results for its second quarter ended June 30, 2026.

globenewswire.com - 2026-08-06 07:00:00

First Trust Advisors LP boosted its position in shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) by 287.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 60,258 shares of the medical equipment provider's stock after acquiring an additional

defenseworld.net - 2026-08-05 03:45:40

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Lantheus Holdings, Inc. (NASDAQ: LNTH) PR Newswire

gurufocus.com - 2026-08-03 16:00:00

NEW YORK, Aug. 3, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Lantheus Holdings, Inc. (NASDAQ: LNTH ) related to its sale to Curium US Holdings LLC.

prnewswire.com - 2026-08-03 15:23:00

Are SUPN, ITGR, ATKR, LNTH Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Aug. 3, 2026

gurufocus.com - 2026-08-03 14:00:00

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws

prnewswire.com - 2026-08-03 13:41:00

Shareholder Alert: Ademi LLP investigates whether Lantheus Holdings, Inc. is obtaining a Fair Price for Public Shareholders PR Ne

gurufocus.com - 2026-08-03 12:00:00

MILWAUKEE, Aug. 3, 2026 /PRNewswire/ -- Ademi LLP is investigating Lantheus (NASDAQ: LNTH) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Curium. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.

prnewswire.com - 2026-08-03 11:13:00

Curium said it would pay $102.50 a share in cash for Lantheus, a 2.9% premium to Friday's closing price of $99.64 and 8.5% above Lantheus's closing price of $94.47 on May 21, before Bloomberg reported that Curium was circling the company.

wsj.com - 2026-08-03 10:58:00

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Lantheus Holdings, Inc. (NASDAQ: LNTH) to Curium US Holdings LLC for $102.50 per sha

gurufocus.com - 2026-08-03 10:00:00

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Lantheus Holdings, Inc. (NASDAQ: LNTH) to Curium US Holdings LLC for $102.50 per share in cash, plus non-transferable Contingent Value Rights providing for up to $12.00 per share in potential additional cash payments, subject to achievement of specified commercial milestones for Lantheus' products through 2030. Halper Sadeh encourages Lantheus shareholders to click here to learn more about the.

businesswire.com - 2026-08-03 09:36:00

BOSTON and BEDFORD, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Curium™, a leading, global radiopharmaceutical company with proven expertise in the development, manufacturing and supply of radiopharmaceuticals that improve the way cancer is diagnosed and treated, and Lantheus Holdings, Inc. (“Lantheus” or “Company”) (NASDAQ: LNTH), today announced that Curium US Holdings LLC (“Curium US”) and Lantheus have entered into a definitive agreement under which Lantheus, a leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, will merge with a wholly-owned subsidiary of Curium US.

globenewswire.com - 2026-08-03 07:31:00

Dimensional Fund Advisors LP trimmed its stake in shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) by 2.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,379,570 shares of the medical equipment provider's stock after selling 35,893 shares during the period. Dimensional

defenseworld.net - 2026-07-29 03:39:50

Terumo (OTCMKTS:TRUMY - Get Free Report) and Lantheus (NASDAQ: LNTH - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, analyst recommendations, risk, dividends and valuation. Profitability This table compares Terumo and Lantheus' net margins, return

defenseworld.net - 2026-07-26 01:59:11

BEDFORD, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, August 6, 2026, to discuss its financial results and provide a business update for the second quarter of 2026.

globenewswire.com - 2026-07-23 08:30:00

Leading pharmaceutical executive brings over 4 decades of commercial, M&A, and governance leadership Leading pharmaceutical executive brings over 4 decades of commercial, M&A, and governance leadership

globenewswire.com - 2026-07-15 13:13:00

On Friday, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter to Lantheus Holdings Inc.'s (NASDAQ:LNTH) New Drug Application (NDA) for LNTH-2501 (Gallium 68 edotreotide), a PET diagnostic imaging kit targeting somatostatin receptor-positive neuroendocrine tumors.

benzinga.com - 2026-06-29 09:51:22

The U.S. ​Food and ‌Drug Administration declined ​to ​approve Lantheus Holdings' ⁠diagnostic imaging ​kit ​for types of cancer tumors, ​citing ​unresolved manufacturing-related conditions ‌at ⁠a third-party facility, the ​company ​said ⁠on Friday.

reuters.com - 2026-06-26 16:12:49

BEDFORD, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for LNTH-2501 (Gallium 68 edotreotide), a PET diagnostic imaging kit targeting somatostatin receptor-positive (SSTR+) neuroendocrine tumors (NETs).

globenewswire.com - 2026-06-26 16:01:00

Lantheus Holdings, Inc. (LNTH) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-09 11:12:12

BEDFORD, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better patient outcomes, today announced John Wiggins, Vice President, External Manufacturing, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference at 8:40 a.m.

globenewswire.com - 2026-06-03 08:30:00

BEDFORD, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that an image generated using LNTH-2513 (18F-GP1) PET/CT was awarded SNMMI's Image of the Year at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting in Los Angeles, California. The recognition was presented in connection with investigator-initiated trial results evaluating LNTH-2513 PET/CT for the detection of acute lower-extremity deep vein thrombosis (DVT) in symptomatic patients.

globenewswire.com - 2026-06-02 08:00:00

BEDFORD, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better patient outcomes, today announced John Wiggins, Vice President, External Manufacturing, will participate in a fireside chat at the William Blair 46th Annual Growth Stock Conference at 12:10 p.m. ET on Wednesday, June 3.

globenewswire.com - 2026-05-27 08:30:00

Lantheus Holdings ​is weighing ‌a potential sale ​after ​getting a takeover ⁠offer from ​private-equity ​backed Curium Pharma that could ​value ​it at about $7 ‌billion, ⁠Bloomberg News reported on ​Friday, ​citing ⁠people familiar ​with ​the ⁠matter.

reuters.com - 2026-05-22 16:27:59

BEDFORD, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced new radiodiagnostic data to be presented at the 2026 Society of Nuclear Medicine and Medical Imaging (SNMMI) Annual Meeting, taking place May 30 – June 2, 2026 in Los Angeles, CA.

globenewswire.com - 2026-05-21 08:30:00

BEDFORD, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced data to be featured at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026 in Chicago, IL.

globenewswire.com - 2026-05-19 08:30:00

Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers face looming patent cliffs and hunt for growth.

247wallst.com - 2026-05-14 09:20:55